Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromuro, indacaterolo maleato - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - ulunar breezhaler è indicato come trattamento broncodilatatore di mantenimento per alleviare i sintomi in pazienti adulti con malattia polmonare ostruttiva cronica (bpco).

İtalya - İtalyanca - AIFA (Agenzia Italiana del Farmaco)

boehringer ingelheim italia s.p.a. - cimetropio bromuro - cimetropio bromuro

İtalya - İtalyanca - AIFA (Agenzia Italiana del Farmaco)

boots pharmaceuticals s.r.l. - butilscopolamina bromuro - butilscopolamina bromuro

İtalya - İtalyanca - AIFA (Agenzia Italiana del Farmaco)

sanofi s.r.l. - butilscopolamina bromuro - butilscopolamina bromuro

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

İtalya - İtalyanca - AIFA (Agenzia Italiana del Farmaco)

gekofar s.r.l. - butilscopolamina bromuro - butilscopolamina bromuro

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionato, formoterolo fumarato diidrato, glycopyrronium bromuro - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Avrupa Birliği - İtalyanca - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionato, formoterolo fumarato diidrato, glycopyrronium - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - trattamento di mantenimento in pazienti adulti con moderata a grave malattia polmonare ostruttiva cronica (bpco) che non sono adeguatamente trattati da una combinazione di un corticosteroide per via inalatoria e un beta2-agonista long-acting (per effetti il controllo dei sintomi e prevenzione delle esacerbazioni vedere sezione 5.

İtalya - İtalyanca - AIFA (Agenzia Italiana del Farmaco)

medifarm s.r.l. - butilscopolamina bromuro - butilscopolamina bromuro

İtalya - İtalyanca - AIFA (Agenzia Italiana del Farmaco)

as kalceks - butilscopolamina bromuro - butilscopolamina bromuro